ArticleFrontiers in endocrinology2026
COVID-19 associated CKM syndrome progression in diabetic patients is linked to pancreatic beta cell dysfunction, rather than RASi use: a retrospective cohort study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: SARS-CoV-2 primarily has tissue tropism for the respiratory epithelium; however, it may cause multiple organ dysfunction due to the widespread expression of its entry receptor, ACE2. Specifically, SARS-CoV-2 may enter pancreatic β-cells by exploiting ACE2, disrupting cellular and hormonal activity, and thereby worsening Cardiovascular-Kidney-Metabolic (CKM) syndrome prognosis in diabetic patients. Furthermore, treatment with renin-angiotensin system inhibitors (RASi) may arguably increase ACE2 expression and facilitate viral entry, making its independent impact highly debated. Accordingly, we sought to elucidate the genuine impact of RASi usage on CKM progression via Propensity Score Matching (PSM) and concurrently investigate the specific contribution of pancreatic β-cell secretory dysfunction. Methods: We conducted a retrospective investigation involving 682 diabetic patients across CKM stages 2 to 4 with confirmed SARS-CoV-2 infection utilizing multivariate logistic regression coupled with 1:1 PSM to rectify selection bias concerning RASi administration and identifying predictors. Results: Post-infection CKM progression was observed in 25.2% of the cohort and while initial multivariate models implicated RASi (OR = 1.56, 95% CI: 1.06-2.28; p=0.02) as a risk factor this association lost statistical significance after rigorously balancing baseline characteristics through PSM (OR = 1.56, 95% CI: 0.91-2.67; p = 0.156). A paradoxical finding emerged wherein the progression group exhibited low HOMA-IR scores accompanied by reduced fasting C-peptide and elevated glucose thereby indicating severe viral-induced β-cell secretory dysfunction rather than enhanced insulin sensitivity while High-Density Lipoprotein Cholesterol (HDL-C) persisted as a protective factor. Conclusions: COVID-19 exacerbates CKM progression in diabetic patients, but this is not driven by RASi therapy itself. RASi use should be interpreted as a "marker of severity" for baseline comorbidities, rather than a pathogenic factor. Mechanistically, viral infection may cause the failure of compensatory mechanisms in pancreatic β-cell function (manifested as low C-peptide and spurious low HOMA-IR).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.